 This is the first study using PF-03758309, an oral compound, in patients with advanced solid tumors. In this study different doses of PF-03758309 will be administered to different groups of patients. The study will assess the compounds safety, the blood levels of PF-03758309 during the treatment and the effect of the compound on the tumor cells. 